quinazolines has been researched along with Hypoglycemia in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 13 (92.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Emser, A; Gallwitz, B; Rosenstock, J; von Eynatten, M; Woerle, HJ | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Barnett, AH; Lewin, AJ; McGill, JB; Neubacher, D; Patel, S; von Eynatten, M; Woerle, HJ | 1 |
| Crowe, S; Del Prato, S; Gong, Y; Groop, PH; Owens, DR; Patel, S; Taskinen, MR; von Eynatten, M; Woerle, HJ | 1 |
| Bajaj, M; Gilman, R; Kempthorne-Rawson, J; Lewis-D'Agostino, D; Patel, S; Woerle, HJ | 1 |
| Barnett, AH; Hehnke, U; Patel, S; Schernthaner, G; von Eynatten, M; Woerle, HJ | 1 |
| Dugi, KA; Gallwitz, B; Hehnke, U; Mehlburger, L; Patel, S; Rosenstock, J; von Eynatten, M; Woerle, HJ | 1 |
| Broedl, UC; DeFronzo, RA; Kaste, R; Lewin, A; Liu, D; Patel, S; Woerle, HJ | 1 |
| Barnett, AH; Gallwitz, B; Groop, PH; Hehnke, U; Laakso, M; Patel, S; Rosenstock, J; Tamminen, I; von Eynatten, M; Woerle, HJ | 1 |
| Bhattacharya, S; Gong, Y; Park, SW; Patel, S; Pinnetti, S; Seck, T; Sheu, WH; Woerle, HJ | 1 |
| Neumiller, JJ; Setter, SM | 1 |
| Arvay, L; Lewin, AJ; Liu, D; Patel, S; von Eynatten, M; Woerle, HJ | 1 |
| Barnett, AH; Harper, R; Patel, S; Thiemann, S; Toorawa, R; von Eynatten, M; Woerle, HJ | 1 |
| Coppi, E; Corradetti, R; Pedata, F; Pugliese, AM; Spalluto, G | 1 |
3 review(s) available for quinazolines and Hypoglycemia
| Article | Year |
|---|---|
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.
Topics: Adult; Aged; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Placebos; Purines; Quinazolines; Randomized Controlled Trials as Topic; Severity of Illness Index | 2014 |
Review of linagliptin for the treatment of type 2 diabetes mellitus.
Topics: Adult; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Purines; Quinazolines | 2012 |
10 trial(s) available for quinazolines and Hypoglycemia
| Article | Year |
|---|---|
Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years.
Topics: Analysis of Variance; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds; Treatment Outcome; Weight Gain | 2013 |
Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Kidney; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Renal Insufficiency, Chronic; Retrospective Studies; Severity of Illness Index; Sulfonylurea Compounds | 2014 |
Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Pioglitazone; Purines; Quinazolines; Thiazolidinediones; Treatment Failure; Treatment Outcome; Weight Gain | 2014 |
Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years.
Topics: Aged; Aged, 80 and over; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Incidence; Linagliptin; Male; Purines; Quinazolines; Treatment Outcome | 2014 |
Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Risk; Sulfonylurea Compounds; Time Factors; Young Adult | 2015 |
Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
Topics: Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Treatment Outcome; Weight Loss | 2015 |
Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Purines; Quinazolines; Sulfonylurea Compounds | 2015 |
Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Treatment Outcome; Weight Gain | 2015 |
Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Aged; Analysis of Variance; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds; Treatment Outcome | 2012 |
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds; Treatment Outcome | 2012 |
1 other study(ies) available for quinazolines and Hypoglycemia
| Article | Year |
|---|---|
A3 adenosine receptor antagonists delay irreversible synaptic failure caused by oxygen and glucose deprivation in the rat CA1 hippocampus in vitro.
Topics: Action Potentials; Adenosine A3 Receptor Antagonists; Animals; Brain Ischemia; Hippocampus; Hypoglycemia; Hypoxia; Male; Pyridines; Quinazolines; Rats; Rats, Wistar; Receptor, Adenosine A3; Synaptic Transmission; Time Factors; Triazoles | 2006 |